[go: up one dir, main page]

AR103867A1 - Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos - Google Patents

Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos

Info

Publication number
AR103867A1
AR103867A1 ARP160100591A ARP160100591A AR103867A1 AR 103867 A1 AR103867 A1 AR 103867A1 AR P160100591 A ARP160100591 A AR P160100591A AR P160100591 A ARP160100591 A AR P160100591A AR 103867 A1 AR103867 A1 AR 103867A1
Authority
AR
Argentina
Prior art keywords
tim3
antibodies
derivatives
cells
fragments
Prior art date
Application number
ARP160100591A
Other languages
English (en)
Inventor
Krapf Irina
Zhou Heyue
Dixon Gray John
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of AR103867A1 publication Critical patent/AR103867A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Composiciones y métodos relacionados o derivados de anticuerpos anti-TIM3. Más específicamente, se divulgan anticuerpos completamente humanos que se unen a TIM3, fragmentos de unión al anticuerpo TIM3 y derivados de dichos anticuerpos, y polipéptidos de unión a TIM3 que comprenden dichos fragmentos. Además, se divulgan ácidos nucleicos que codifican dichos anticuerpos, fragmentos de anticuerpo y derivados y polipéptidos, células que comprenden dichos polinucleótidos, métodos de elaboración de dichos anticuerpos, fragmentos de anticuerpo y derivados y polipéptidos, y métodos de uso de dichos anticuerpos, fragmentos de anticuerpo y derivados y polipéptidos, incluyendo métodos de tratamiento de enfermedades de cáncer, autoinmune e inflamatoria.
ARP160100591A 2015-03-06 2016-03-04 Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos AR103867A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562129321P 2015-03-06 2015-03-06

Publications (1)

Publication Number Publication Date
AR103867A1 true AR103867A1 (es) 2017-06-07

Family

ID=56849611

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100591A AR103867A1 (es) 2015-03-06 2016-03-04 Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos

Country Status (12)

Country Link
US (2) US9873741B2 (es)
EP (1) EP3265486A4 (es)
JP (1) JP2018510151A (es)
KR (1) KR20180008405A (es)
CN (1) CN107922484A (es)
AR (1) AR103867A1 (es)
AU (1) AU2016229189A1 (es)
CA (1) CA2978892A1 (es)
IL (1) IL254260A0 (es)
MX (1) MX2017011406A (es)
TW (1) TW201639888A (es)
WO (1) WO2016144803A2 (es)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
WO2015042707A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
TW201632559A (zh) 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
CA2978892A1 (en) * 2015-03-06 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
TR201911032T4 (tr) 2015-05-18 2019-08-21 Tolero Pharmaceuticals Inc Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
MA44659B1 (fr) * 2016-04-12 2021-12-31 Symphogen As Anticorps anti-tim-3 et compositions
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
AU2017271588B2 (en) 2016-05-27 2022-01-20 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2018013818A2 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
KR102585976B1 (ko) 2016-08-17 2023-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
TWI665216B (zh) * 2016-12-29 2019-07-11 財團法人生物技術開發中心 抗人類tim-3抗體及其使用方法
US11345753B2 (en) 2017-02-27 2022-05-31 Jiangsu Hengrui Medicine Co., Ltd. TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereof
EP3606957A1 (en) 2017-04-05 2020-02-12 Symphogen A/S Combination therapies targeting pd-1, tim-3, and lag-3
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP3630180A1 (en) 2017-06-01 2020-04-08 Compugen Ltd. Triple combination antibody therapies
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11542312B2 (en) 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2018287519B2 (en) 2017-06-22 2021-07-22 Novartis Ag IL-1beta binding antibodies for use in treating cancer
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
JP2020525483A (ja) 2017-06-27 2020-08-27 ノバルティス アーゲー 抗ｔｉｍ−３抗体のための投与レジメンおよびその使用
JP2020527572A (ja) 2017-07-20 2020-09-10 ノバルティス アーゲー 抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
WO2019023410A1 (en) 2017-07-28 2019-01-31 Phanes Therapeutics, Inc. ANTI-TIM-1 ANTIBODIES AND USES THEREOF
MX2020001980A (es) 2017-08-28 2020-03-24 Bristol Myers Squibb Co Antagonistas de celulas t con dominios de inmunoglobulina y mucina 3 (tim-3) para el tratamiento y diagnostico de canceres.
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
JP2021511372A (ja) 2018-01-16 2021-05-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｍ３に対する抗体で癌を処置する方法
AU2019215031B2 (en) 2018-01-31 2025-10-09 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
CN110144011B (zh) * 2018-02-14 2020-06-23 上海洛启生物医药技术有限公司 针对t淋巴细胞免疫球蛋白黏蛋白3的单域抗体
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
CN116789827A (zh) 2018-04-12 2023-09-22 南京维立志博生物科技有限公司 应用tim-3结合抗体治疗疾病的方法
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
IL317554A (en) 2018-06-01 2025-02-01 Novartis Ag Anti-BCMA binding molecules and their uses
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
LT3820573T (lt) 2018-07-10 2023-11-10 Novartis Ag 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diono dariniai ir jų naudojimas gydyti nuo ikaros šeimos cinko pirštų 2 (ikzf2) priklausomas ligas
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020038355A1 (zh) 2018-08-20 2020-02-27 江苏恒瑞医药股份有限公司 Tim-3抗体在制备治疗肿瘤的药物中的用途
JP2022513553A (ja) 2018-08-28 2022-02-09 ジエンス ヘンルイ メデイシンカンパニー リミテッド 抗ｔｉｍ３抗体医薬組成物およびその使用
CN113166245B (zh) 2018-09-27 2024-12-20 细胞基因公司 SIRPα结合蛋白及其使用方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
JP2022511029A (ja) 2018-12-04 2022-01-28 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
CN113195538B (zh) * 2018-12-12 2023-03-14 上海药明生物技术有限公司 抗tim-3抗体及其用途
AU2019402151B2 (en) 2018-12-20 2022-12-08 Novartis Ag Combinations of a HDM2-p53 interaction inhibitor and a BCL2 inhibitor and their use for treating cancer
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
AU2019409139A1 (en) 2018-12-21 2021-06-03 Novartis Ag Use of IL-1β binding antibodies
AU2019408408A1 (en) 2018-12-21 2021-06-03 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
US20200369762A1 (en) 2018-12-21 2020-11-26 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
AU2020205735A1 (en) * 2019-01-11 2021-08-05 Minerva Biotechnologies Corporation Anti-variable MUC1* antibodies and uses thereof
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
CN113747895A (zh) 2019-03-22 2021-12-03 大日本住友制药肿瘤公司 包含pkm2调节剂的组合物和用其治疗的方法
US20200318200A1 (en) 2019-04-02 2020-10-08 The Brigham And Women's Hospital, Inc. Methods for Identifying Progression of a Primary Melanoma
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
EP4041394A1 (en) 2019-09-16 2022-08-17 Novartis AG Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
IL292347A (en) 2019-10-21 2022-06-01 Novartis Ag Combination treatments with ventoclax and tim-3 inhibitors
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
MX2022008771A (es) 2020-01-14 2022-10-07 Synthekine Inc Metodos y composiciones de muteinas de il2 sesgadas.
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
KR102536302B1 (ko) * 2020-02-25 2023-05-26 국립암센터 Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN113214396B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
EP4083065A1 (en) 2021-01-28 2022-11-02 NantBio, Inc. Anti-tim3 monoclonal antibodies and chimeric antigen receptors
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
MX2023012060A (es) 2021-04-13 2024-01-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4372006A4 (en) * 2021-07-16 2025-10-08 Brightpath Biotherapeutics Co Ltd ANTIBODY OR ANTIBODY DERIVATIVE TO TIM-3 ANTIGEN, AND USE THEREOF
US20250339522A1 (en) 2021-10-15 2025-11-06 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
CN118660964A (zh) 2021-12-16 2024-09-17 瓦莱里奥治疗公司 新型缀合核酸分子及其用途
TW202345900A (zh) * 2022-03-14 2023-12-01 大陸商正大天晴藥業集團南京順欣製藥有限公司 抗tim-3抗體與去甲基化藥物的藥物組合
KR20240159621A (ko) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 폴리펩티드를 단리하는 방법
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
JP2025518785A (ja) 2022-06-02 2025-06-19 ブリストル－マイヤーズ スクイブ カンパニー 抗体組成物及びその使用方法
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025068461A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025068452A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025132831A1 (en) 2023-12-19 2025-06-26 Universite D'aix-Marseille N-heteroaryl derivatives and uses thereof for treating cancer
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025262250A1 (en) 2024-06-20 2025-12-26 Negio Therapeutics Guanfacine derivatives and their uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814383D0 (en) * 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
EP3020413A1 (en) * 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
ES2571235T3 (es) * 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
PT2581113T (pt) * 2010-06-11 2018-07-04 Univ Kyushu Nat Univ Corp Anticorpo anti-tim-3
JP2013532153A (ja) * 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
CN106432495A (zh) 2010-07-22 2017-02-22 加利福尼亚大学董事会 抗肿瘤抗原抗体及其使用方法
US8841418B2 (en) * 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
CN110294807B (zh) * 2014-10-27 2023-05-12 新加坡科技研究局 抗tim-3抗体
CN107001475B (zh) * 2014-11-06 2021-01-29 豪夫迈·罗氏有限公司 抗tim3抗体及使用方法
CA2978892A1 (en) * 2015-03-06 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3

Also Published As

Publication number Publication date
US9873741B2 (en) 2018-01-23
US20160257758A1 (en) 2016-09-08
EP3265486A4 (en) 2018-11-14
KR20180008405A (ko) 2018-01-24
TW201639888A (zh) 2016-11-16
AU2016229189A1 (en) 2017-09-21
MX2017011406A (es) 2018-06-19
CA2978892A1 (en) 2016-09-15
WO2016144803A8 (en) 2016-11-17
JP2018510151A (ja) 2018-04-12
WO2016144803A2 (en) 2016-09-15
CN107922484A (zh) 2018-04-17
IL254260A0 (en) 2017-10-31
EP3265486A2 (en) 2018-01-10
US10927171B2 (en) 2021-02-23
WO2016144803A3 (en) 2016-10-13
US20180251549A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
AR103867A1 (es) Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos
MX2021007947A (es) Terapeuticos de anticuerpo que se unen a ctla4.
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
MX382398B (es) Proteinas de union a antigeno st2.
MX2017007537A (es) Anticuerpos anti-pd-1 y sus metodos de uso.
MX2019014318A (es) Proteinas de union a nectina-4 y metodos de uso de las mismas.
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
PE20170772A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de union a antigeno, una composicion farmaceutica y uso
CO7160115A2 (es) Proteinas de unión a antigeno que se unen a pd-l1
BR112018068678A2 (pt) anticorpos anti-mica
HK1221964A1 (zh) 与pd-1结合的抗原结合蛋白
DOP2016000282A (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
EA201690503A1 (ru) Антитела
MX2017001263A (es) Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer.
EA201591796A1 (ru) Антитела к cd52
WO2016164657A3 (en) Antibody therapeutics that bind cd123
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3

Legal Events

Date Code Title Description
FB Suspension of granting procedure